Belgium-based UCB has opened its Asia-Pacific region Headquarters inthe Malaysian city of Petaling Jaya in order to integrate the group's three business divisions. UCB, whose regional pharma HQ was moved from Singapore to Malaysia in July last year, is expecting to achieve double-digit sales growth in 2002. The Asia-Pacific market contributes about 25% of the company's total sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze